View Sample PDF

Listen to Interview with Author
(Right-click link and select "Save Target As...")

The area of gene expression reagents is one of the newest and most important sectors of pharmaceutical and bioscience research and development. The term gene expression reagents refers to chemicals that are used in gene expression experiments that are performed to determine whether a particular gene is expressed--i.e., present--and in some cases at what levels, in a biological sample. The purpose of this TriMark Publications report is to describe the specific segments of the global gene expression reagents market. Within this area, the study covers those segments that are highly active in terms of innovation and growth. Specifically, this review examines the markets for gene expression reagents and small lab equipment all the way up to highly automated platforms. Emphasis is on those companies that are actively developing and marketing gene expression reagents for genomics research in the academic sector and the pharmaceutical, bioscience industry. This study concentrates on the laboratory reagent market segment and the companion gene expression reagents sector in the U.S. and around the world that use materials for genetic research. Particular attention is paid to those areas of the gene expression reagents sector that are showing the greatest growth or the most innovation. The report attempts to answer the following questions:

• What companies are the key players?
• What is the market for gene express reagents?
• What are the opportunities in gene expression reagents markets?
• What are the developing trends?
• Where are the new market growth areas?
• What are the most favored technology platforms?
• Where are the gene expression reagent technologies taking researchers?
• How are gene expression reagent technologies blending with more established laboratory procedures?
• What are the business trends in the industry?

The study surveys some of the leading companies known to be marketing, manufacturing or developing products for the gene expression reagents market for those sectors covered here. Each company is discussed in depth with a section on the history of the company, the product line, business and marketing analysis, and a subjective commentary of the position of the company in its market. The benefits of this report are:

• In-depth analysis of the major sectors of the gene expression reagent sectors, their size, growth rates and major drivers.
• Presentation of some of the emerging technology platforms, elucidating the potential areas that could gain traction in this market.
• Analysis of the partnerships and alliances the various key sector players have forged, as well as describing financings of these market participants, giving insight into potential market collaborations.
• Examination of new technology platforms that seek to dominate this new market, and to identify lead positions and potential future growth areas.
• An overview of the current state of gene expression assays used in drug development and the numerous opportunities that exist to increase the quality of genetic sequences evaluated.
• A profile of the gene expression customer and an analysis of factors influencing the adoption of specific gene exploration technology.
• A five-year projection of spending on new equipment and reagents.
• Impact of commercial gene reagents on genetic R&D.

1. 1. Overview 5
2. 1.1 Objectives of the Report 5
3. 1.2 Methodology 6
4. 1.3 Scope of the Report 7
5. 1.4 Executive Summary 7
7. 2. Gene Expression 9
8. 2.1 The Genomics Revolution 9
9. 2.2 Basic Principles of Gene Expression 9
10. 2.3.1 Quantitative Real-Time PCR (qRT-PCR) 10
11. 2.3.2 PCR Labeling Chemistries 11
12. 2.3.3 TaqMan® Probes 11
13. 2.3.4 SYBR® Green 11
14. 2.4 Microarray Technology 12
15. 2.5 Microarray Target Preparation and Hybridization 12
16. 2.6 RNA Sample Preparation and Assessment 13
18. 3. Gene Expression Reagents 15
19. 3.1 Kit Format vs. Home-Brew Assays 15
20. 3.2 Whole Product Solutions 15
21. 3.3 Emerging Technologies 16
23. 4. Market Environment 17
24. 4.1 Institutional and Government Budgeting 17
25. 4.2 Worldwide Investment in Genomics Technologies and Research 17
26. 4.3 Industry Consolidation and Acquisitions 18
28. 5. Market Drivers 19
29. 5.1 Improved Assay Performance 19
30. 5.2 Cost Effective Systems 19
31. 5.3 Automation 21
32. 5.4 Bioinformatics Solutions 21
34. 6. Worldwide Market for Gene Expression Reagents 23
35. 6.1 Life Science Research 23
36. 6.2 Drug Discovery and Development, Molecular Diagnostics 23
37. 6.3 Commercial Production 23
38. 6.4 Gene Expression Market Size 23
39. 6.4.1 Real-Time PCR Revenue 25
40. 6.4.2 Commercial Microarray Revenue 25
41. 6.4.3 RNA Sample Preparation Revenue 26
42. 6.5 Gene Expression Reagent Market by Region 26
43. 6.6 Users of Gene Expression Products 27
44. 6.6.1 Core Laboratories 28
45. 6.6.2 Consortia 28
46. 6.6.3 Pharmaceutical and Biotechnology Companies 28
47. 6.7 Affiliation 28
48. 6.8 Job Function and Decision Makers 29
50. 7. Key Applications 32
51. 7.1 BioMarker Identification and Pharmacogenomics 32
52. 7.2 Toxicogenomics 32
53. 7.3 Molecular Diagnostics 32
55. 8. Vendor and Product Selection 33
56. 8.1 Product Adoption 33
57. 8.2 Drivers for Product Switching 34
59. 9. Leading Vendors 35
61. 10. Marketing Strategies 38
62. 10.1 e-Marketing and e-Commerce 38
63. 10.2 Catalog 38
64. 10.3 On-Site Cabinet Programs 39
66. 11. Pricing Strategies 40
67. 11.1 Price Elasticity 40
68. 11.2 Strategies 41
70. 12. Distribution Channels 43
72. 13. Competitive Situation 44
74. 14. Opportunities 47
76. 15. Market Strategy Profiles, Leading and Selected Vendors 48
77. 15.1 Applied Biosystems 48
78. 15.1.1 Applera Corporation-Corporate History and Structure 48
79. 15.1.2 Molecular Biology Technology and Products 49
80. 15.1.3 Acquisitions, Partnerships and Collaborations, 2006 50
81. 15.1.4 Product Portfolio Summary 50
82. 15.1.5 Real-Time PCR/Genomics Products and Consumables 51
83. 15.1.6 Real-Time PCR/Genomics New Product Introductions, 2006 51
84. 15.1.7 End-Users 51
85. 15.1.8 Distribution Channels 52
86. 15.1.9 Competition-Gene Expression Products 52
87. 15.1.10 Competitive Analysis 52
88. 15.1.11 Business Model 52
89. 15.2 Affymetrix 53
90. 15.2.1 Corporate History and Structure 53
91. 15.2.2 Technology 54
92. 15.2.3 Partnerships and Collaborations 54
93. 15.2.4 Product Portfolio Summary 55
94. 15.2.5 Complementary Services 56
95. 15.2.6 New Product Introductions 57
96. 15.2.7 End-Users 57
97. 15.2.8 Distribution Channels 57
98. 15.2.9 Competition 58
99. 15.2.10 Competitive Analysis 58
100. 15.2.11 Business Model 58
101. 15.3 Invitrogen 59
102. 15.3.1 Corporate History and Structure 59
103. 15.3.2 Technology 59
104. 15.3.3 Acquisitions 60
105. 15.3.4 Partnerships and Collaborations 61
106. 15.3.5 Product Profile Summary 61
107. 15.3.6 Gene Expression Product Portfolio 63
108. 15.3.7 New Product Introductions 64
109. 15.3.8 End-Users 64
110. 15.3.9 Distribution Channels 65
111. 15.3.10 Competition 65
112. 15.3.11 Competitive Analysis 65
113. 15.3.12 Business Model 65
114. 15.4 Qiagen 66
115. 15.4.1 Corporate History and Structure 66
116. 15.4.2 Technology 67
117. 15.4.3 Acquisitions, Partnerships and Collaborations 67
118. 15.4.4 Collaborations and Partnerships 68
119. 15.4.5 Product Portfolio Summary 68
120. 15.4.6 Complementary Services 69
121. 15.4.7 New Product Introductions 69
122. 15.4.8 End-Users 70
123. 15.4.9 Distribution Channels 70
124. 15.4.10 Competition 70
125. 15.4.11 Competitive Analysis 70
126. 15.4.12 Business Model 71
127. 15.5 GE Healthcare (Formerly Amersham Biosciences) 71
128. 15.5.1 Corporate History and Structure 71
129. 15.5.2 Technology 72
130. 15.5.3 Product Portfolio Summary 73
131. 15.5.4 Complementary Services 75
132. 15.5.5 Genomics New Product Introductions 75
133. 15.5.6 Amersham Biosciences End-Users 75
134. 15.5.7 Distribution Channels 75
135. 15.5.8 Competition 75
136. 15.5.9 Competitive Analysis 75
137. 15.5.10 Business Model 76
138. 15.6 Stratagene 76
139. 15.6.1 Corporate History and Structure 76
140. 15.6.2 Technology 77
141. 15.6.3 Acquisitions, Collaborations, Alliances and Partnerships 78
142. 15.6.4 Product Portfolio Summary-Research Products Division 78
143. 15.6.5 New Product Introductions 79
144. 15.6.6 Complementary Services 79
145. 15.6.7 End-Users 80
146. 15.6.8 Distribution Channels 80
147. 15.6.9 Competition 80
148. 15.6.10 Competitive Analysis 80
149. 15.6.11 Business Model 81
151. Appendix I: Leading Vendor's Gene Expression Products 82
152. Appendix II: Gene Expression Product Groups 92
153. Appendix III: Companies Offering Gene Expression Products 93
156. LIST OF FIGURES
158. Figure 2.1: Gene Expression Process 9
159. Figure 2.2: qRT-PCR Workflow 11
160. Figure 2.3: Microarray Workflow 13
161. Figure 6.1: Gene Expression Market by Region 26
162. Figure 6.2: Researchers Using Gene Expression Technologies Worldwide, 2005 27
163. Figure 6.3: Distribution of Laboratory Workers by Organization in North America 29
164. Figure 6.4: Laboratory Job Function 29
165. Figure 6.5: Product Selection and Purchasing Decision Makers 30
168. LIST OF TABLES
170. Table 5.1: Microarray Analysis Cost per Sample 20
171. Table 5.2: Cost of qRT-PCR Research Reagents and Systems 20
172. Table 6.1: Five-Year Forecast-Gene Expression Reagents, Instruments 24
173. Table 6.2: RNA Sample Preparation Revenue 24
174. Table 6.3: Forecasted Annual Revenue-qRT-PCR, 2005-2010 24
175. Table 6.4: Forecasted Annual Revenue-Commercial Microarrays, Reagents, Instruments, 2005-2010 24
176. Table 6.5: Forecasted Annual Revenue-Gene Expression Reagents, Instruments, 2005-2010 25
177. Table 6.6: Forecasted Annual Revenue-RNA Sample Preparation, 2005-2010 25
178. Table 6.7: Projected Revenue Growth of Microarrays and Related Products 26
179. Table 6.8: Major Players' Distribution of Revenue by Region, 2005 27
180. Table 6.9: Decision Makers Profile 31
181. Table 9.1: Major Vendors-Gene Expression Reagents and RNA Sample Preparation 35
182. Table 9.2: Vendors' Key Statistics, 2005 36
183. Table 9.3: Vendors' Technology and Products 36
184. Table 11.1: RNA Sample Preparation-Vendors Prices 40
185. Table 11.2: qPCR Kits-Vendor's Prices 41
186. Table 11.3: Reverse Transcriptase-Vendor's Prices 42
187. Table 12.1: Distribution Channels 43
188. Table 15.1: Applied Biosystems Revenue, 2005 48
189. Table 15.2: Affymetrix Revenue, 2005 53
190. Table 15.3: Invitrogen Revenue, 2005 59
191. Table 15.4: Qiagen Revenue, 2005 67
192. Table 15.5: GE Healthcare Revenue, 2005 72
193. Table 15.6: Stratagene Revenue, 2005 77